4Seok JI,Joo IS,Yoon JH,et al.Can aspirin resistance be clinically predicted in stroke patients?[J].Clinical Neurology And Neurosurgery.2008,110(2):110-116.
5Cervera A,Tàssies D,Obach V,et al.The BC genotype of the VNTR polymorphism of platelet glycoprotein Ibalpha is overrepresented in patients with recurrent stroke regardless of aspirin therapy[J].Cerebrovascular Diseases (Basel,Switzerland).2007,24(2-3):242-246.
6The ESPS group.The European stroke prevention study(ESPS):principal end-point[J].Lancet,1987,14:5-14.
7Davis SM,Donnan GA.Secondary prevention for stroke after CAPRIE and ESPS-2.Opinion 1[J].Cerebrovasc Dis,1998,87:73-75.
8Leonardi-Bee J,Bath PM,Bousser MG,et al.Dipyridamole for preventing recurrent ischemic stroke and other vascular events:a meta-analysis of individual patient data from randomized controlled trials[J].Stroke,2005,36:162-168.
9The ESPRIT Study Group.Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin(ESPRIT):randomised controlledtrial[J].Lancet,2006,367:1665-1673.
10Diener HC,Sacco R,Yusuf S.Rationale,design and baseline data of a randomized,double-blind,controlled trial comparing two antithrombotic regimens(a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel)and telmisartan versus placebo in patients with strokes:The Prevention Regimen for Effectively Avoiding Second Strokes Trial(PRoFESS)[J].Cerebrovasc Dis,2007,23:368-380.
2Bhatt DL,Fox KA,Hacke W,et al.CHARISMA Investigators.Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events[J].N Engl J Med,2006,354:1706-1717.
3Diener HC,Bogousslavsky J,Brass LM,et al.MATCH investigators.Aspirin and clopidogrel compared with clopidogrel alone after recent ischemic stroke or transient ischemic attack in high-risk patients (MATCH):randomized,doubleblind,placebo-controlled trial[J].Lancet,2004,364:331-337.
4Sandercock P,Mielke O,Liu M,et al.Anticoagulants for preventing recurrence following presumed non-cardioembolic ischemic stroke or transient ischemic attack (Cochrane Review)[A].In:The Cochrane Database of Systematic Reviews.2002:CD000248.
5Gubitz G,Sandercock P,Counsell C.Anticoagulants for acute ischemic stroke (Cochrane Review)[A].In:The Cochrane Database of Systematic Reviews[M].2004:CD000024.
6Saxena R,Koudstaal PJ.Anticoagulants for preventing stroke in patients with non rheumatic atrial fibrillation and a history of stroke or transient ischemic attack (Cochrane Review)[A].In:The Cochrane Database of Systematic Reviews[M].2004:CD000185.
7PROGRESS Collaborative Group.Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischemic attack[J].Lancet,2001,29,358:1033-1041.
8Lawes CMM,Bennett DA,Feigin VL,et al.Blood pressure and stroke:an overview of published reviews[J].Stroke,2004,35:1024-1033.
9The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) investigators.High-dose atorvastatin after stroke or transient ischemic attack[J].N Engl J Med,2006,355:549-559,613-615.
10American Diabetes Association.ADA clinical practice recommendations[J].Diabetes Care,2004,27:S1-S143.
3Li C,Hedblad B,Rosvall M,et al.Stroke incidence,recurrence,and case-fatality in relation to socioeconomic position:A population based study of middle-aged swedish men and women[J].Stroke,2008,39(8):2191-2196.
4Progress Collaborative Group.Randomised trial of a perindoprilbased blood-pressure lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack[J].Lancet,2001,358(9287):1033-1041.
5van Gijn J.The progress trial:preventing st rokes by lowering blood pressure in patients with cerebral ischemia.Emerging therapies:critique of an important advance[J].Stroke,2002,33(1):391-320.
6Lawes CM,Bennett DA,Feiqin VL,et al.Blood pressure and stroke.an overview of published reviews[J].Stroke,2004,35(4):1024.
8Touzé E,Coste J,Voicu M,et al.Importance of in-hospitalinitiation of therapies and therapeutic inertia in secondary stroke prevention:implementation of prevention after a cerebrovascular event(IMPACT)study[J].Stroke,2008,39(6):1834-1843.
9Hackam DG.Angiotensin receptor blockers should be regarded as first-line drugs for stroke prevention in both primary and secondary prevention settings:Yes[J].Stroke,2009,40(9):3159-3161.
10Papadopoulos DP,Papademetriou V.Aggressive blood pressure control and stroke prevention:role of calcium channel blockers[J].J Hypertens,2008,26(5):844-852.
